Loading stock data…
SYRE
$69.42-5.03 (-6.76%)
Market ClosedLast close May 1
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Spyre Therapeutics, Inc. in the Healthcare sector is trading at $69.42. The stock is currently near its 52-week high of $76.00, remaining 122.3% above its 200-day moving average. Technical signals show neutral RSI of 59 and bearish MACD signal, explaining why SYRE maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 59) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$69.42
Potential Upside
5%
Whystock Fair Value$72.89
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Mean target$90.67+30.6%
Range$64.00 – $115.00
Fundamentals
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.30B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.94
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-28.92%
Volume
Today's trading volume
1.43M
Recent News
Spyre Therapeutics (SYRE) Is Up 7.5% After Positive SKYLINE Data And $463.5 Million Raise
Spyre Therapeutics recently reported positive Phase 2 SKYLINE trial results for its SPY001 antibody in moderate-to-severe ulcerative colitis, and in mid-April closed an underwritten public offering that raised about US$463.5 million in gross proceeds. The combination of encouraging efficacy and dosing data for SPY001 with a sizeable capital raise gives Spyre more resources to advance long-acting and combination antibody therapies for inflammatory bowel disease and rheumatic...
Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now?
Spyre Therapeutics Inc. (NASDAQ:SYRE) is one of the small-cap stocks that are on fire right now. On April 16, Spyre Therapeutics successfully closed an underwritten public offering, generating ~$463.5 million in gross proceeds. The final total reflects the full exercise of the underwriters’ option to purchase an additional 975,000 shares, bringing the total number of […]
Spyre Therapeutics (SYRE): Favorite Stock of Elite Money Managers
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Spyre Therapeutics, Inc. (NASDAQ:SYRE) ranks 4th on this list. Following a string of clinical successes in early April, Spyre Therapeutics, Inc. (NASDAQ:SYRE) stock has become a favorite for managers looking to capitalize on the multi-billion dollar Inflammatory Bowel Disease market. […]
Here’s What Raymond James Says About Spyre Therapeutics Inc (SYRE)
Spyre Therapeutics Inc (NASDAQ:SYRE) is among the best 52-week high US stocks to buy. On April 16, Spyre Therapeutics Inc (NASDAQ:SYRE) said in a press release that it raised around $463.5 million in gross proceeds from its recent equity offering. The company offered 7.48 million shares of its common stock, and granted the underwriters the […]
Spyre (SYRE) Climbs 42% as Treatment Candidate Poses ‘Best-in-Class’ Potential
Spyre Therapeutics Inc. (NASDAQ:SYRE) is one of the 10 Stocks With Monster Returns. Spyre Therapeutics grew its share prices by 42.3 percent week-on-week, as investors took heart from the “best-in-class” potential of its therapy candidate for ulcerative colitis (UC). In an updated report earlier in the week, Spyre Therapeutics Inc. (NASDAQ:SYRE) said that its treatment […]